Aperio Group LLC boosted its stake in Allergan PLC. (NYSE:AGN) by 11.2% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 134,258 shares of the company’s stock after buying an additional 13,508 shares during the period. Aperio Group LLC’s holdings in Allergan PLC. were worth $32,637,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of AGN. Veritas Asset Management LLP purchased a new position in Allergan PLC. during the first quarter valued at approximately $761,339,000. Edgewood Management LLC boosted its position in Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock valued at $646,090,000 after buying an additional 178,055 shares in the last quarter. Epoch Investment Partners Inc. boosted its position in Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after buying an additional 73,081 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in Allergan PLC. by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock valued at $476,713,000 after buying an additional 5,042 shares in the last quarter. Finally, Blue Ridge Capital L.L.C. boosted its position in Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares in the last quarter. 84.77% of the stock is currently owned by hedge funds and other institutional investors.
Allergan PLC. (NYSE AGN) traded up 0.29% on Friday, hitting $232.88. 1,820,899 shares of the stock were exchanged. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The company has a 50-day moving average of $245.93 and a 200 day moving average of $238.13. The firm has a market cap of $77.85 billion, a P/E ratio of 7.10 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same period last year, the company posted $3.35 EPS. The business’s revenue was up 8.8% on a year-over-year basis. Equities research analysts expect that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.20%. Allergan PLC.’s payout ratio is currently 9.95%.
COPYRIGHT VIOLATION WARNING: This piece was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.baseball-news-blog.com/2017/08/13/aperio-group-llc-has-32-64-million-position-in-allergan-plc-agn-updated-updated.html.
AGN has been the topic of several recent analyst reports. BidaskClub cut shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Wednesday. Citigroup Inc. reissued a “focus list” rating and set a $261.27 target price (up previously from $184.50) on shares of Allergan PLC. in a research report on Friday, April 21st. Deutsche Bank AG reaffirmed a “buy” rating and issued a $273.00 price target (up previously from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Goldman Sachs Group, Inc. (The) cut shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target on the stock. in a report on Wednesday, May 10th. Finally, Royal Bank Of Canada lifted their price target on shares of Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a report on Wednesday, May 10th. Eight research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Allergan PLC. presently has an average rating of “Buy” and an average price target of $274.49.
In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.